生物制剂和小分子药物治疗炎症性肠病不良反应的研究进展

打开文本图片集

Advances in StudyonAdverse Reactionsof Biological Agentsand Small Molecule Drugs in Treatment of InflammatoryBowelDiseaseWANGXiaojuan’，PENGBingxial，DAIShixue²，SHAWeihong2.'TheFirstClinical Medical Collge，Gannan Medical University，GanzhouJiangxi Province （341ooo）;²Departmentof Gastroenterology， GuangdongProvincialPeople'sHospital （GuangdongAcademyofMedicalSciences），SouthernMedicalUniversityGuagzo Correspondence to：SHA Weihong，Email： wh-sha@163.com

AbstractInflammatory bowel disease （IBD）isanimmune-mediated inflammatory disorder with high heterogeneity. Thetreatmentsafetyparticularlyadversereactions，isakeyfocusareaforphysicians.Currently，thebiologicalagentsand small molecule drugs in treatment of IBD，such as anti-tumor necrosis factor- α agents，anti-integrinagents，interleukin （IL）- 12/IL-23-targeting agents，and Januskinase （JAK） inhibitors，sphingosine-1-phosphate （S1P）receptor modulators，can induce both acute and chronic adverse reactions.Chronic adverse reactions mainly manifest as opportunistic infection， malignancies in different organs，especially lymphoma，aswellasadversereactions in thecardiovascularand nervous systems.Thisarticlereviewed theresearch progressonadversereactionsofbiologicalagentsandsmall moleculedrugs in treatment of IBD.

Key wordsInflammatory Bowel Disease; Biological Agents; SmallMoleculeDrugs;AdverseReactions

炎症性肠病（inflammatoryboweldisease，IBD）是一种慢性非特异性胃肠道炎症性疾病，以活动期与缓解期交替出现为特征，包括克罗恩病（Crohn'sdisease，CD）和溃疡性结肠炎（ulcerativecolitis，UC）。（剩余16142字）